ResMed (RMD) is scheduled to report Q1 earnings on October 29, 2026. Analysts estimate EPS of $2.7 and quarterly revenue of $1.4B.
In the most recent quarter (Q4), ResMed reported EPS of $2.95, beating estimates of $2.88 by 0.02%. Revenue came in at $1.46B, exceeding the estimate of $1.46B by 0%.
ResMed has beaten EPS estimates in 8 consecutive quarters.
Over the last 4 quarters, ResMed has averaged an EPS surprise of 0.03% and a revenue surprise of 0.01%.
Earnings Date
Oct 29
EPS Estimate
$2.700
Quarterly Revenue Estimate
$1.4B
Annual Revenue
$5.65B
as of Jun 30
Analyze the earnings history of ResMed using advanced sorting and filters.
The chart below shows ResMed's reported EPS compared to analyst estimates over recent quarters.
The chart below shows ResMed's reported revenue compared to analyst estimates over recent quarters.
ResMed (RMD) is scheduled to report earnings on October 29, 2026. The last reported earnings were for reported on August 6, 2026 for Q4.
The Actual EPS was $2.95, which beat the estimate of $2.88.
The Actual Revenue was $1.46B, which beat the estimate of $1.46B.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | Aug 6, 2026 | $2.95 | $2.88 | 2.43 % |
| Q3 | Apr 30, 2026 | $2.86 | $2.80 | 2.14 % |
| Q2 | Jan 29, 2026 | $2.81 | $2.71 | 3.69 % |
| Q1 | Oct 30, 2025 | $2.55 | $2.50 | 2.00 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | Aug 6, 2026 | $1.46B | $1.46B | 0.09 % |
| Q3 | Apr 30, 2026 | $1.43B | $1.42B | 0.67 % |
| Q2 | Jan 29, 2026 | $1.42B | $1.39B | 2.00 % |
| Q1 | Oct 30, 2025 | $1.34B | $1.33B | 0.62 % |